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2a: Problem identification and description of need 
• Herpes zoster (‘shingles’) is a viral infection that results in a painful 
rash. (5) 
• Post-herpetic neuralgia is a long-term complication of shingles that 
cannot be treated by antiviral medications. (2) 
• Over the last 20 years, incidence of shingles has increased by nearly 
50%. (1) 
• Zostavax, the first shingles-prevention vaccine, was approved by the 
FDA in 2006. (6) 
• Approved for patients 60 years and older 
• Shingrix, a new vaccine, was approved in 2017 and is now the 
preferred shingles vaccine per the CDC. (5) 
• Approved for patients 50 years and older 
2b: Problem identification and need, cont. 
• Shingrix has shown to have better outcomes than Zostavax, reducing 
incidence of shingles and post-herpetic neuralgia. (5) 
• Patients are only beginning to become aware of and curious about 
Shingrix. 
• To address improving patient education, I developed a brochure that 
gives patients information about shingles, Shingrix, and answers some 
frequently asked questions.  
 
3. Public health cost  
 
• Total annual costs of Shingles in the US  
• 2011-2012: $1,997,183. (1)  
• Total costs have held relatively constant over last 20 years. 
• Increasing incidence and rising medical and prescription costs. 
• Medical costs increased from $57.98/episode in 1997/98 to $78.84/episode in 2013/14. 
• Decreasing rates of hospitalization over this time. 
• Shingles incidence increases with age- and an aging population 
increases likelihood that costs will increase in the future. (3) 
4. Community Perspective on Shingrix 
• Kathy McCoy, APRN- Brookfield Family Practice 
• States that this vaccine is revolutionizing the response to shingles, as it is so much more 
effective and is safe, even for immunosuppressed patients, since it is not a live vaccine. 
• Notes patients may feel unwell after receiving Shingrix- more fatigue and myalgias- but says 
this is a sign that the body is producing a robust immune response. It is actually a good thing, 
and it will resolve quickly. 
 
• Maggie Litwin, MPH- Program Coordinator, Immunization & Community Health Worker Initiative, 
Southwestern CT AHEC 
• Agency covers Bridgeport area, works with the Department of Public Health, and does 
provider education and public outreach. Majority of work with older populations happens 
during community health fairs. 
• States that patients are very interested in Shingles vaccination and have many questions on 
whether or not they should receive the vaccine. AHEC provides general information and 
points them towards their PCPs for specifics. 
• Shingrix is now being purchased for uninsured populations in the local communities, starting 
in March, 2018. Providers are able to order the vaccine for those without insurance at no 
cost. 
• Twice a year, there is an IAP advisory committee meeting which educates providers on a 
variety of topics. A GSK Pharmaceuticals spokesperson is speaking at this meeting in May 




5. Intervention and Methodology  
 
• Produced a patient information brochure using evidence-based 
sources. 
• Distributed to office managers at both Brookfield and Newtown 
Family Practice clinics for use in waiting rooms. 
• Goal is to increase patient awareness of the new vaccine and to 
encourage conversation between patient and provider. 
 
 
6. Results/Response Data 
 
• Positive response from providers.  
• There is great support for Shingrix already, despite its newness. 
• Having informed patients is an important step to having successful shared 
decision making. 
• Patients are interested in learning more. 
• The majority of patients are interested in vaccination, as many have had 
friends or family who have suffered from shingles, and they do not want to 
have that experience themselves.  
• Common concerns included coverage by individual insurance plans, and 
reservations about receiving Shingrix if they have had Shingles, received 
Zostavax, are feeling sick, etc. 
 
 
7. Evaluation of effectiveness and limitations 
• Assessing effectiveness of this project was difficult due to time constraints. 
• To evaluate this intervention, assessment of the following would be 
interesting: 
• Monitoring the number of conversations regarding shingles vaccination and Shingrix 
that are initiated by the patient. 
• Assessing patient knowledge of the available preventive measures. 
• Comparing rates of vaccination with Shingrix in Newtown and Brookfield vs. national 
data. 
• Limitations include: 
• Newness of the vaccine and limited insurance coverage by Medicaid and private 
insurers at this time. 




8. Recommendations for future interventions/projects  
 
• Assess the rates of vaccination with Shingrix in the eligible population 
as awareness of Shingrix increases. 
• Compare rates of vaccination with Shingrix to historical data 
from Zostavax. 
• Look at vaccination rates with Shingrix in patients who have already 
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